HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulating CBD As Drug Will ‘Kill The Hemp Sector’, Says EU Industry

Executive Summary

European Industrial Hemp Association warns regulating CBD supplements as drugs will see the EU fall behind other markets such as the US and fuel the development of an unregulated black market. 

You may also be interested in...



Highest European Court Rules CBD Is Not A Narcotic Drug

The European Court of Justice rules that CBD cannot be regarded as a narcotic as it is non-psychoactive and suggests that a French ban on the cannabinoid is contrary to EU law on the free movement of goods. Legal experts and industry hope the judgment will pave the way for a regulated European CBD market.

UN Vote On Cannabis Controls Could Be Crucial To CBD’s Future In EU

Legal experts say the EU already prohibits cosmetic use of CBD sourced from hemp flowers, and it now appears that food supplement use could be held to the same standard. The World Health Organization has recommended changes to the half-century-old international treaty governing narcotic controls, which could help to resolve the situation, but there are reports of UN pushback.

European Hemp Players Join Forces To Make Legal CBD Market A Reality

Europe's hemp industry is tired of operating in limbo and wants to secure a fully regulated CBD market as soon a possible. Industry players will pool resources and invest €3.5m to win novel food approval for a number of different CBD products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel